Antibody against myelin oligodendrocyte glycoprotein is introduced as a diagnostic marker and can be used as a prognostic factor in patients with a seronegative anti-NMO, facilitating diagnosis of a subgroup of NMOSD. The gene discussed is MOG; the disease is neuromyelitis optica.